TY  - JOUR
T1  - Plasminogen Activator Inhibitor-1-675 4G/5G and Methylenetetrahydrofolate Reductase Gene Variants in Young Acute Myocardial Infarction and Juvenile Ischemic Stroke
AU - , Giulia Bivona AU - , Chiara Bellia AU - , Salvatore Cammarieri AU - , Bruna Lo Sasso AU - , Rosachiara Carollo AU - , Rosalinda Raineri AU - , Gaia Chiarello AU - , Antonietta Caruso AU - , Marcello Ciaccio 
JO  - Research Journal of Biological Sciences
VL  - 3
IS  - 11
SP  - 1341
EP  - 1343
PY  - 2008
DA  - 2001/08/19
SN  - 1815-8846
DO  - rjbsci.2008.1341.1343
UR  - https://makhillpublications.co/view-article.php?doi=rjbsci.2008.1341.1343
KW  - Thrombophilia
KW  -stroke
KW  -myocardial infarction
KW  -gene variants
KW  -plasminogen
AB  - Cardiovascular diseases often recognize a hereditary-familial genetic risk patterns and a substantial proportion of variability in clinical features of atherosclerosis could probably be explained by genetic factors. Aim of this study is to compare prevalence of factor V Leiden, factor II 20210A, PAI-1-675 4G/5G and MTHFR C677T gene variants in 2 cardiovascular disease clinical features: young acute myocardial infarction (<50 years) and ischemic stroke. Plasminogen Activator Inhibitor-1-675 4G/5G didn’t show significant difference between patients and controls while, between patient groups, the polymorphism was most present in myocardial infarction group than in juvenile stroke. Polymorphisms in Homocysteine metabolism: MTHFR C677T variants was significantly higher in patients with myocardial infarction compared with those affected by ischemic Stroke.
ER  -